FindTrial
Sign In

The role and mechanism of pericyte in temozolomide resistance of glioma

The role and mechanism of pericyte in temozolomide resistance of glioma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047925
Enrollment
Unknown
Registered
2021-06-27
Start date
2021-07-01
Completion date
Unknown
Last updated
2022-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

case series:None

Sponsors

the First Affiliated Hospital of Army Medical University, PLA
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with WHO grade III or IV glioma. 2. The films were re-read by more than 2 pathologists and a definite diagnosis of glioma was made.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
CD146;CCL5;—

Countries

China

Contacts

Public ContactPing Yifang

Army Medical University of PLA

pingyifang@126.com+86 18623448461

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026